SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Reveles Xavier Trinidad
(Last) (First) (Middle)
C/O BIOAFFINITY TECHNOLOGIES, INC.,
22211 WEST INTERSTATE 10, SUITE 1206
(Street)
SAN ANTONIO, TX 78257
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2023 		3. Issuer Name and Ticker or Trading Symbol
bioAffinity Technologies, Inc. [ BIAF ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 3,619(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) 06/07/2018 05/07/2028 Common Stock 2,857(2) 7.7 D
Stock Option (Right to Buy) 03/25/2019 02/25/2029 Common stock 1,428(2) 7.7 D
Stock Option (Right to Buy) 03/05/2020 02/05/2030 Common Stock 1,428(2) 7.7 D
Stock Option (Right to Buy) 08/26/2021 07/26/2031 Common Stock 2,142(2) 7.7 D
Explanation of Responses:
1. This restricted stock award was granted on November 17, 2022 and vest pro rata monthly over one year.
2. This stock option is fully vested and reflects a stock split that occurred on June 23, 2022.
Remarks:
Exhibit List - Exhibit 24.1: Power of Attorney (Xavier Reveles)
/s/ Xavier Trinidad Reveles 09/25/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.